Pressure Biosciences Inc (PBIO)

[NetworkNewsWire]

PBIO Enters Co-Marketing, Distribution Agreement with ISS, Inc.

Pressure BioSciences (OTCQB: PBIO) this morning said it has entered a two-year, global co-marketing and distribution agreement with ISS, Inc. The companies intend to combine the ISS high pressure optical cell with Pressure BioSciences’ automated high pressure instrument resulting in an exceptional analytical system with the potential to substantially improve biopharmaceutical drug discovery and development. High pressure optical spectroscopy is gaining popularity among scientists worldwide for its unique and effective way to look at molecular interactions. The new ISS/PBI instrument system is set to be unveiled at the annual Biophysical Society Meeting (“BPS”) which begins on February 17th in San Francisco, CA. “Interfacing the PBI HUB 440/880 pressure generators with the ISS high pressure optical cell system will allow scientists to visualize and measure pressure effects on molecular interactions and protein conformation as the reactions are taking place in the optical cell – in real time. This novel capability should help scientists better understand how proteins function and interact with other biomolecules, which is critically important in the development of better, more effective diagnostics and pharmaceuticals,” Pressure BioSciences VP of R&D, Dr. Alexander Lazarev stated in the news release.

To view the full press release, visit http://nnw.fm/bEJ4m

About Pressure BioSciences Inc.

Pressure BioSciences Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. PBI’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of PBI’s patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.